Questions discussed in this category
Patient is asymptomatic. Labs showed +P-ANCA 1:160. Negative MPO and PR3.
Vasculitis activity has been assessed with serial CTA of the chest and head/neck. She has existing right axillary artery disease and new areas of invo...
How would you treat? Would you view tocilizumab as an option in the future?
The ADVOCATE trial only studied use for 52 weeks.
Would you proceed with CABG procedure or treat the aortitis first?
Other manifestations improved (renal function has stabilized, fatigue, arthritis, and LCV have resolved). Ophthalmologist has controlled the uveitis u...
In a patient for whom rituximab is the best option for their disease management.
Is there a role of rituximab therapy over repeat cyclophosphamide? (Cyclophosphamide induction 2 years prior)
When would you consider tapering? at one year? 18 months?
At what CD 19/20 level do you redose? Is this lab dependent?
Do you also use these levels to instruct patients when to get vaccinated?
MPO/PR3, P-ANCA negative. IgG4 normal.
Would the checkpoint inhibitor still work if blocking only that portion of the inflammatory cascade as opposed to more global blockade with steroids?
What are your primary and secondary agents?
Would you obtain imaging? If so, what type of imaging?
Is there a role for monitoring for relapse or increased disease activity as opposed to scheduled dosing?
Is there role for IVIG? Would you alter the dose or time course of steroid therapy?
In your experience, are there specific disease manifestations in which HLAB51 is particularly helpful?
Other than inflammatory markers and following symptoms/exam, do you need any other specific monitoring for progression to systemic disease?
Would you suggest switching to a viral vector vaccine, such as J&J?
How does this vary from continued disease monitoring?
Additionally, what is the current role for temporal artery ultrasound in workup for GCA?
Do you obtain vascular imaging routinely in these cases, and if so, do you use cross-sectional or invasive angiography?
Thoughts on sarilumab vs methotrexate, or just treat with steroids alone
Small study in pediatric PACNS have evaluated this as a potential marker (Cellucci et al., PMID 22740622)
There are multiple difficulties that could be seen: steroids can precipitate a sickle cell crisis, vasculitis and sickle cell can produce similar clin...
Would you change rituximab maintenance dose or schedule?
Specifically, do you reach for Rituximab or cyclophosphamide?
E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...
In the ADVOCATE trial, patients were not re-dosed with rituximab.
Given the slow recovery of nerve damage, what would you expect to see on a repeat EMG after treatment? Continued denervation or just sequelae of past ...
What if the patient has MGUS?
Do patients with type 1 cryoglobulins need a bone marrow biopsy as part of the work up?
How would you label such a patient?
Would you treat differently if they have poor functional status?
This question is part of a collaboration with RheumMadness and is in reference to: Pathogenic ANCARAVE Trial
If you use both, how do you decide which to use for a particular patient?
17665176311733917017169391668114129142201654215876157341426215087150881506714864148221466614586132721425313977124541365113538134351345513353126781073512988128551275912763120361241612443120991193611468111061089511534111461135110974107371062210618838810450102751026710218100619755942297009614956794219417882789929348932286219234890388868853888585428686848584797314834784738428841683558282811880718083801479677966786873137115
Papers discussed in this category
The New England journal of medicine, 2010-07-15
Medicine (Baltimore),
The New England journal of medicine, 2010-07-15
,
Ann. Rheum. Dis., 2018 Apr 25
Ann. Rheum. Dis., 2017 May 25
Ann. Rheum. Dis., 2018 May 03
Medicine, 1976-05
Arthritis and rheumatism, 2010-01
J. Rheumatol., 2019 Sep 01
Annals of the rheumatic diseases, 2009-03
BJR Case Rep, 2018 Sep 08
Ann Intern Med, 2020 Sep 22
Curr Rheumatol Rep, 2020 Oct 16
N Engl J Med,
Lancet, 2016 Mar 04
JAMA network open, 2018-11-02
Rheumatol Int, 2020 Sep 18
The New England journal of medicine, 2017-05-18
Kidney international reports, 2018-03
N Engl J Med, 2020 Feb 13
Rheumatology (Oxford),
The Journal of rheumatology, 2012-02
Rheumatology (Oxford, England), 2011-12
Nat Rev Neurol,
Nat Rev Dis Primers, 2018 Aug 02
N Engl J Med, 2021 Feb 18
Rheumatology (Oxford),
Ann Intern Med,
Ann Rheum Dis, 2011 Nov 29
Annals of internal medicine, 1994-06-15
Front Neurol, 2019 Jun 06
Curr Opin Rheumatol,
Arthritis Rheum,
Seminars in arthritis and rheumatism, 2012-06
Arthritis Rheumatol, 2021 Jul 08
Ann Rheum Dis, 2019 Jul 03
Radiographics : a review publication of the Radiological Society of North America, Inc, 2001
International journal of clinical rheumatology, 2010
Mayo Clin Proc,
Seminars in arthritis and rheumatism, 2016-02
Bull Soc Ophtalmol Fr,
Am J Hum Genet, 2021 Jan 7
Ann Rheum Dis, 2021 Jul 02
RMD Open, 2021 Sep
J Dermatol,
Arthritis Rheum,
J Am Acad Dermatol, 2021 Jul 02
Arthritis Care Res (Hoboken), 2020 May 19
J Rheumatol, 2021 Feb 15
Rheumatology (Oxford),
Eur J Cancer, 2021 Sep 15
Thorac Cancer, 2020 Feb 11
The New England journal of medicine, 2013-08-01
N Engl J Med,
N Engl J Med,
Rheumatol Int, 2014 Jun 05
Heart, 2021 Feb 16
Arthritis Rheumatol, 2019 Nov 04
Arthritis Rheumatol, 2022 Jun 20
Journal of vascular surgery, 2006-01
Rheumatology (Oxford), 2022 Jul 06
Clin Exp Rheumatol, 2022 Nov 02
Mayo Clinic proceedings, 2018-11
Kidney Int, 2017 May 12
Arthritis Rheumatol, 2020 Sep 6